NO970257D0 - Bestemmelse av tonisk ovarie-östrogen sekresjon i utvidede terapeutiske regimer - Google Patents

Bestemmelse av tonisk ovarie-östrogen sekresjon i utvidede terapeutiske regimer

Info

Publication number
NO970257D0
NO970257D0 NO970257A NO970257A NO970257D0 NO 970257 D0 NO970257 D0 NO 970257D0 NO 970257 A NO970257 A NO 970257A NO 970257 A NO970257 A NO 970257A NO 970257 D0 NO970257 D0 NO 970257D0
Authority
NO
Norway
Prior art keywords
determination
therapeutic regimens
estrogen secretion
extended therapeutic
tonic
Prior art date
Application number
NO970257A
Other languages
English (en)
Norwegian (no)
Other versions
NO970257L (no
Inventor
Gary D Hodgen
Audrey Philips
Original Assignee
Hampton Roads Medical College
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26959766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO970257(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/467,860 external-priority patent/US5658884A/en
Application filed by Hampton Roads Medical College, Ortho Pharma Corp filed Critical Hampton Roads Medical College
Publication of NO970257D0 publication Critical patent/NO970257D0/no
Publication of NO970257L publication Critical patent/NO970257L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO970257A 1994-07-22 1997-01-21 Bestemmelse av tonisk ovarie-östrogen sekresjon i utvidede terapeutiske regimer NO970257L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27959394A 1994-07-22 1994-07-22
US08/467,860 US5658884A (en) 1994-07-22 1995-06-06 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
PCT/US1995/008996 WO1996003138A1 (fr) 1994-07-22 1995-07-18 Procede pour assurer une secretion tonique d'oestrogene ovarien dans des regimes therapeutiques de longue duree

Publications (2)

Publication Number Publication Date
NO970257D0 true NO970257D0 (no) 1997-01-21
NO970257L NO970257L (no) 1997-01-21

Family

ID=26959766

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970257A NO970257L (no) 1994-07-22 1997-01-21 Bestemmelse av tonisk ovarie-östrogen sekresjon i utvidede terapeutiske regimer

Country Status (29)

Country Link
EP (1) EP0769956B1 (fr)
JP (1) JP3138477B2 (fr)
CN (1) CN1137722C (fr)
AP (1) AP775A (fr)
AT (1) ATE190494T1 (fr)
AU (1) AU691952B2 (fr)
BG (1) BG63363B1 (fr)
BR (1) BR9508718A (fr)
CA (1) CA2195745C (fr)
CY (1) CY2228B1 (fr)
CZ (1) CZ291803B6 (fr)
DE (1) DE69515666T2 (fr)
DK (1) DK0769956T3 (fr)
EE (1) EE03515B1 (fr)
ES (1) ES2145286T3 (fr)
FI (1) FI970244A (fr)
GR (1) GR3033590T3 (fr)
HU (1) HU218910B (fr)
IL (1) IL114655A (fr)
IS (1) IS4413A (fr)
LV (1) LV11823B (fr)
MX (1) MX9700574A (fr)
NO (1) NO970257L (fr)
NZ (1) NZ290554A (fr)
OA (1) OA10730A (fr)
PT (1) PT769956E (fr)
RU (1) RU2181598C2 (fr)
SK (1) SK282118B6 (fr)
WO (1) WO1996003138A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173592B1 (en) 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
NZ534836A (en) * 1999-09-23 2007-07-27 Zentaris Gmbh Method for the therapeutic management of extrauterine proliferatoin of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
GB0616111D0 (en) * 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
EP2095818A1 (fr) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Utilisation d'antagonistes LHRH dans des doses n'impliquant pas de castration
US20110129532A1 (en) * 2008-05-29 2011-06-02 Isr Immune System Regulation Ab Method and means for treating viral disease, in particular hiv/aids
WO2016184829A1 (fr) * 2015-05-18 2016-11-24 Nerre Therapeutics Limited Antagonistes doubles des récepteurs nk-1/nk-3 pour le traitement de maladies dépendant des hormones sexuelles
EP3560555A1 (fr) * 2018-04-26 2019-10-30 LifeArc Composition pour traiter une ou plusieurs maladies liées aux strogènes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5169932A (en) * 1989-10-30 1992-12-08 The Salk Institute For Biological Studies Gnrh analogs
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease

Also Published As

Publication number Publication date
JP3138477B2 (ja) 2001-02-26
AP9700913A0 (en) 1997-01-31
ATE190494T1 (de) 2000-04-15
IL114655A (en) 2005-08-31
DK0769956T3 (da) 2000-06-05
JPH10503203A (ja) 1998-03-24
OA10730A (en) 2001-06-07
AP775A (en) 1999-10-28
EE9700208A (et) 1998-02-16
CY2228B1 (en) 2003-04-18
FI970244A0 (fi) 1997-01-21
ES2145286T3 (es) 2000-07-01
HU218910B (hu) 2000-12-28
EP0769956B1 (fr) 2000-03-15
NZ290554A (en) 2000-08-25
RU2181598C2 (ru) 2002-04-27
WO1996003138A1 (fr) 1996-02-08
IL114655A0 (en) 1995-11-27
LV11823A (lv) 1997-08-20
EE03515B1 (et) 2001-10-15
PT769956E (pt) 2000-07-31
CN1200674A (zh) 1998-12-02
CZ291803B6 (cs) 2003-06-18
DE69515666T2 (de) 2000-07-06
IS4413A (is) 1997-01-14
HUT77127A (hu) 1998-03-02
CZ15097A3 (en) 1997-11-12
HU9700046D0 (en) 1997-02-28
SK7097A3 (en) 1997-11-05
EP0769956A4 (fr) 1999-03-10
GR3033590T3 (en) 2000-09-29
AU3132095A (en) 1996-02-22
BG101158A (en) 1997-09-30
BG63363B1 (bg) 2001-11-30
NO970257L (no) 1997-01-21
EP0769956A1 (fr) 1997-05-02
DE69515666D1 (de) 2000-04-20
LV11823B (en) 1998-03-20
MX9700574A (es) 1997-12-31
AU691952B2 (en) 1998-05-28
CN1137722C (zh) 2004-02-11
FI970244A (fi) 1997-01-21
CA2195745A1 (fr) 1996-02-08
BR9508718A (pt) 1997-12-30
CA2195745C (fr) 2005-03-29
SK282118B6 (sk) 2001-11-06

Similar Documents

Publication Publication Date Title
DE69609353D1 (de) In der therapie verwendbare chinolin- und chinazolinverbindungen
DE69505657D1 (de) Fluorcarbonetherhybriden enthaltende physiologich akzeptabele emulsionen und verwendungsverfahren
NO972125D0 (no) Hemmoroideblandinger og fremgangsmåte for anvendelse
FI972681A (fi) Kynsien sientenvastainen käsittely
EE9800158A (et) Epinastiin kasutamiseks valude ravis
ID15858A (id) Turunan triazol yang berguna dalam terapi
ID18679A (id) Penggunaan terapi lanjutan
DE4480717T1 (de) Tiefwasser-Übungs- und Therapiebecken
FI953423A0 (fi) Temotsolomidin tehostaminen ihmisten kasvainsoluissa
DK295190D0 (da) Kosmetik- og hudbehandlingssammensaetninger
NO970257D0 (no) Bestemmelse av tonisk ovarie-östrogen sekresjon i utvidede terapeutiske regimer
FI954964A (fi) vWF-pitoisten konsentraattien käyttö yhdistelmäterapiana antitromboottisilla ja fibrinolyyttisillä lääkeaineilla suoritettavassa terapiassa
DE69522489T2 (de) Haarkräftigungsmittel
KR960033565U (ko) 지압 및 쑥뜸 겸용 지압구
LV11523A (lv) Domperidona pielietosana kardalgijas arstesana
LV10916A (lv) Metoklopramida lietosana kardalgijas arstesana
KR970044605U (ko) 냉동실의 급속냉동칸의 구조
FI961492A0 (fi) Terapeutiskt och profylaktiskt foerfarande foer bekaempande av skadliga mikrober och aemnen
SE9604300D0 (sv) Therapeutical use and method
FIU970096U0 (fi) Allasmainen kiuas
KR870009601U (ko) 건조기겸 사우나 욕실
SE8604881D0 (sv) Alkylglycerolernas effekt vid cancerterapi
FIU920720U0 (fi) I stomkonstruktioner anvaendbart foerbindningsdel
KR960004995U (ko) 높이조절이 가능한 곽티슈의 케이스
SE9302237D0 (sv) Uppblaasbart/uppumpningsbart och formeftergivligt haestsko-sulinlaegg

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application